© 2020 AJMC. All rights reserved.
Sebastian Schneeweiss, MD, ScD, professor of medicine and epidemiology, Harvard Medical School and Brigham and Women's Hospital, and co-founder of Aetion, explains how rapid cycle analytics of real-world evidence can be used to evaluate the safety and efficacy of newly approved drugs.
Sebastian Schneeweiss, MD, ScD, professor of medicine and epidemiology, Harvard Medical School and Brigham and Women's Hospital, and co-founder of Aetion, explains how rapid cycle analytics of real-world evidence can be used to evaluate the safety and efficacy of newly approved drugs.
Transcript
Can rapid-cycle analytics of real-world evidence be used for evaluation the safety and efficacy of newly approved drugs?
Yes. So, our platform is, for example, used by the FDA, and we appreciate that the FDA is asking slightly different questions than the payer organizations. Nevertheless, both of these organizations care for patients, they have responsibilities, and they want to work with the best evidence possible. So, we validate to get it with the FDA that our platform is able to identify the effectiveness and the safety of medications as they’re used in routine care. And the payers working with our platform have the benefit of getting the same strength of evidence in their own populations, so they know then how well the medication works in their own population rather than having to extrapolate from national data or from randomized trial data.